Celgene Acquires Abraxis for $2.9 Billion

Loading...
Loading...
Celgene's purchase expands the company into the solid tumor cancer drug market.
Market News and Data brought to you by Benzinga APIs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...